DEDIFFERENTIATED LIPOSARCOMA
Clinical trials for DEDIFFERENTIATED LIPOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new DEDIFFERENTIATED LIPOSARCOMA trials appear
Sign up with your email to follow new studies for DEDIFFERENTIATED LIPOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo aims to halt aggressive fat tissue cancer
Disease control Recruiting nowThis study is testing whether combining two drugs, mirdametinib and palbociclib, is safe and effective for people with advanced liposarcoma that has spread, returned, or cannot be surgically removed. Researchers will first find the safest dose of mirdametinib to give with a fixed…
Matched conditions: DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New Triple-Action pill enters human testing in fight against tough cancers
Disease control Recruiting nowThis is a first-in-human study to test the safety and find the right dose of a new oral drug, OKN4395, for people with advanced solid tumors. The trial will give the drug alone and combined with an existing immunotherapy (pembrolizumab) to about 166 participants with cancers like…
Matched conditions: DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE1 • Sponsor: Epkin • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC